Physician profile
Eileen K Plotkin
NPI 1346565520
$4,507.28
in general payments reported to CMS, 2019-2025
27 companies · $1,530 in 2025
The $1,530 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $203 · 2022: $97.90 · 2023: $748 · 2024: $1,306 · 2025: $1,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,568 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,567.57 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $964.94 | 2019-2025 | |
| Janssen Biotech, INC. | $543.61 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $469.51 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $405.86 | 2019-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $283.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $213.70 | 2023-2025 | Ocaliva |
| Genzyme Corporation | $205.24 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $172.87 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $131.85 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $126.48 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $116.74 | 2023-2025 | Dupixent |
| Celgene Corporation | $109.51 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $93.63 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $92.94 | 2025 | Sucraid |
| Covidien LP | $91.88 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $81.05 | 2024-2025 | Omvoh |
| Allergan, INC. | $74.26 | 2019-2020 | |
| Novo Nordisk INC | $73.26 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $50.88 | 2023-2024 | Rebyota |
| Nestle Healthcare Nutrition INC. | $49.70 | 2023 | |
| Pfizer INC. | $46.70 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $29.36 | 2025 | Zenpep |
| Fujifilm Healthcare Americas Corporation | $28.28 | 2023 | Fujifilm |
| Exact Sciences Corporation | $22.94 | 2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $14.89 | 2019 | |
| Shire North American Group INC | $13.28 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Plotkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.